Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
ISTH- |
RCV002222015 | SCV002499572 | likely pathogenic | von Willebrand disease type 1 | criteria provided, single submitter | clinical testing | ||
Quest Diagnostics Nichols Institute San Juan Capistrano | RCV000086718 | SCV004221528 | pathogenic | not provided | 2023-02-06 | criteria provided, single submitter | clinical testing | The frequency of this variant in the general population, 0.000004 (1/250414 chromosomes, http://gnomad.broadinstitute.org), is uninformative in assessment of its pathogenicity. In the published literature, the variant has been reported in individuals with vWD Type 2B (PMIDs: 1373334 (1992), 9723578 (1998), 17155947 (2007), 26345337 (2015), 28436749 (2017), and 28971901 (2017)) and in individuals with unspecified vWD Type 2 (PMIDs: 17155947 (2007) and 33556167 (2021)). Family studies show that this variant segregates with vWD Type 2 or 2B (PMIDs: 1373334 (1992) and 17155947 (2007)). Inconclusive functional studies for this variant show enhanced ristocetin-induced platelet aggregation, normal or reduced ratios of ristocetin cofactor to vWF antigen, reduced collagen binding to vWF antigen ratio, and normal or reduced high molecular weight multimers (PMIDs: 17155947 (2007), 25185554 (2014), and 26345337 (2015)). Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, this variant is classified as pathogenic. |
Academic Unit of Haematology, |
RCV000086718 | SCV000118923 | not provided | not provided | no assertion provided | not provided | ||
Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, |
RCV002243734 | SCV002513377 | uncertain significance | von Willebrand disease type 2 | 2022-04-26 | no assertion criteria provided | clinical testing |